Compare Adaptive Biotechnologies Corp (ADPT) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs SiTime Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $24.94 (market cap $4.04B), while SiTime Corporation trades at $695.37 (market cap $20.05B). The key difference: SiTime Corporation is far larger — about 5× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| ADPT | SITM | |
|---|---|---|
Market Cap | $4.04B | $20.05B |
Sector | Health | Technology |
52-Week High | $25.45 | $901.60 |
52-Week Low | $12.30 | $212.77 |
Enterprise Value | $4.10B | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
SiTime Corporation (SITM) trades at $697.50, up 1.09% with strong bullish technical signals and consistent earnings beats. The stock shows robust revenue growth, expanding margins, and positive analyst sentiment with a $870 consensus price target. Recent Q2 2026 results exceeded expectations with 127% revenue growth, driven by AI infrastructure demand and the Renesas acquisition.
Outlook remains positive with AI timing growth as the key catalyst, though premium valuation and integration risks warrant caution. The stock offers significant upside potential from current levels but faces execution risks in scaling operations and maintaining margin expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
